| First Author | Mori T | Year | 2019 |
| Journal | J Biol Chem | Volume | 294 |
| Issue | 8 | Pages | 2714-2731 |
| PubMed ID | 30563837 | Mgi Jnum | J:348420 |
| Mgi Id | MGI:6304851 | Doi | 10.1074/jbc.RA118.004280 |
| Citation | Mori T, et al. (2019) Combined treatment with the phenolics (-)-epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice. J Biol Chem 294(8):2714-2731 |
| abstractText | "Nutraceuticals" are well-tolerated natural dietary compounds with drug-like properties that make them attractive as Alzheimer's disease (AD) therapeutics. Combination therapy for AD has garnered attention following a recent National Institute on Aging mandate, but this approach has not yet been fully validated. In this report, we combined the two most promising nutraceuticals with complementary anti-amyloidogenic properties: the plant-derived phenolics (-)-epigallocatechin-3-gallate (EGCG, an alpha-secretase activator) and ferulic acid (FA, a beta-secretase modulator). We used transgenic mice expressing mutant human amyloid beta-protein precursor and presenilin 1 (APP/PS1) to model cerebral amyloidosis. At 12 months of age, we orally administered EGCG and/or FA (30 mg/kg each) or vehicle once daily for 3 months. At 15 months, combined EGCG-FA treatment reversed cognitive impairment in most tests of learning and memory, including novel object recognition and maze tasks. Moreover, EGCG- and FA-treated APP/PS1 mice exhibited amelioration of brain parenchymal and cerebral vascular beta-amyloid deposits and decreased abundance of amyloid beta-proteins compared with either EGCG or FA single treatment. Combined treatment elevated nonamyloidogenic soluble APP-alpha and alpha-secretase candidate and down-regulated amyloidogenic soluble APP-beta, beta-C-terminal APP fragment, and beta-secretase protein expression, providing evidence for a shift toward nonamyloidogenic APP processing. Additional beneficial co-treatment effects included amelioration of neuroinflammation, oxidative stress, and synaptotoxicity. Our findings offer preclinical evidence that combined treatment with EGCG and FA is a promising AD therapeutic approach. |
